ClinicalTrials.gg
CompletedNCT03334253MTS1Updated Jul 31, 2026Results posted

Low-Dose Atropine for Treatment of Myopia

A Phase 3 interventional study of Atropine and Placebo Eyedrops in Myopia, sponsored by Jaeb Center for Health Research. Completed at 13 sites in United States. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Jaeb Center for Health Research · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing atropine in Myopia — 17 open to participants now, 24 under way, 9 of them phase 3. Atropine · Myopia.

Enrollment
21st of 54
200 · median 144
Started
2018
with 6 others
Phase 3
13 of 54
5 open now
Registered
9th of 54
by date
Lead sponsor
2 of 54
Jaeb Center for Health Research

Among the 54 studies testing atropine in Myopia, this one is the 21st largest by enrollment, is one of 7 that started in 2018, is one of 13 in phase 3, and was the 9th registered.

Myopia

1,162 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

17 of the 54 studies testing atropine in Myopia are open now, in 11 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About atropine

Atropine: first FDA approval 1960 (LOMOTIL), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.

This study: 5 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing atropine in Myopia, or all of them as a file.
02

Study summary

Study Objectives

The objectives for this randomized trial are:

  1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia progression over a two-year treatment period in children aged 5 to less than 13 years (Primary Outcome On-Treatment).
  2. To determine the efficacy of atropine treatment on myopia progression 6 months following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment).

Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.

Read the detailed description

Study Objectives

The objectives for this randomized trial are:

  1. To determine the efficacy of daily low-dose atropine (0.01%) for slowing myopia progression over a two-year treatment period in children aged 5 to less than 13 years with myopia -1.00 to -6.00D at the time of enrollment (Primary Outcome On-Treatment).
  2. To determine the efficacy of atropine treatment on myopia progression 6 months following cessation of low-dose atropine treatment (Secondary Outcome Off-Treatment).

Synopsis of Study Design The current study is designed as an efficacy study, making effort to maximize adherence to treatment group assignments. After a run-in phase during which all participants are treated with daily artificial tear eyedrops for 2-4 weeks (and glasses are updated if required) to assess their ability to adhere to daily eye drops, participants are randomly assigned to daily atropine or placebo for 24 months, followed by 6 months off treatment.

03

Conditions studied

  • Myopia

Browse trials for

Keywords

  • Myopia
  • atropine
04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 5 years to \<13 years at time of enrollment. Children within 4 weeks of their 13th birthday are not eligible.
  • Refractive error meeting the following by cycloplegic autorefraction:

    • Myopia -1.00D to -6.00D spherical equivalent (SE) in both eyes
    • Astigmatism \<=1.50D in both eyes
    • Anisometropia \<1.00D SE
  • Gestational age ≥ 32 weeks.
  • Birth weight >1500g.
  • Parent understands the protocol and is willing to accept randomization to atropine or placebo.
  • Is willing to participate in a 2 to 4 week run-in phase using daily artificial tear eyedrops.
  • Able to return in 2 to 4 weeks for possible randomization.
  • Parent has a phone (or access to phone) and is willing to be contacted by Investigator's site staff.
  • Relocation outside of the area of an active PEDIG site within next 32 months is not anticipated.

Exclusion criteria

Exclusion Criteria:

  • Current or previous myopia treatment with atropine, pirenzepine or other anti-muscarinic agent.
  • Current or previous use of bifocals, progressive-addition lenses, or multi-focal contact lenses.
  • Current or previous use of orthoK, rigid gas permeable, or other contact lenses being used to reduce myopia progression.
  • Known atropine allergy.
  • Abnormality of the cornea, lens, central retina, iris or ciliary body.
  • Current or prior history of manifest strabismus, amblyopia, or nystagmus.
  • Prior eyelid, strabismus, intraocular, or refractive surgery.
  • Down syndrome or cerebral palsy.
  • Females who are pregnant, lactating, or intending to become pregnant within the next 30 months.

    • A negative urine pregnancy test will be required for all females who have experienced menarche.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
200 participants (actual)

Study arms

  • Experimental
    Atropine Group

    0.01% atropine eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off atropine eyedrops

    Drug: Atropine

  • Placebo comparator
    Placebo Group

    Placebo eyedrops administered 1 drop to each eye daily in each eye for 24 months, followed by 6 months off placebo eyedrops

    Other: Placebo Eyedrops

Interventions

  • Daily 0.01% atropine eyedrops

    Also known as: Low-Dose Atropine

  • OtherPlacebo Eyedrops

    Daily placebo eyedrops

06

What researchers measure

Primary outcomes

  1. Treatment Group Comparison of Change in Spherical Equivalent Refractive Error.

    The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

    Time frame: At 24 months

  2. Primary Outcome Measure Stratified by Sex

    NIH-required analysis. Primary outcome measure (stratified by sex): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

    Time frame: at 24 months

  3. Primary Outcome Measure Stratified by Race

    NIH-required analysis. Primary outcome measure (stratified by race): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

    Time frame: by 24 months

  4. Primary Outcome Measure Stratified by Ethnicity

    NIH-required analysis. Primary outcome measure (stratified by ethnicity): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

    Time frame: at 24 months

  5. Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months

    The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.

    Time frame: 24 months

Secondary outcomes

  1. Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent

    Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.

    Time frame: At 30 months

07

Results

Posted May 11, 2023

Participant flow

Participant flow — Overall Study
MilestoneAtropine GroupPlacebo Group
Started12562
Completed11857
Not completed75
Withdrew: Withdrawal by subject10
Withdrew: Lost to follow-up43
Withdrew: Moved residence22

Outcome measures

PrimaryTreatment Group Comparison of Change in Spherical Equivalent Refractive Error.

The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Time frame:
At 24 months
Reported as:
Count of participants · Participants
Treatment Group Comparison of Change in Spherical Equivalent Refractive Error.
ParticipantsAtropine GroupPlacebo Group
<=-3.50 Diopters00
>-3.50 to -3.00 Diopters10
>-3.00 to -2.50 Diopters10
>-2.50 to -2.00 Diopters52
>-2.00 to -1.50 Diopters87
>-1.50 to -1.00 Diopters199
>-1.00 to -0.50 Diopters3718
>-0.50 to 0.00 Diopters4618
>0 Diopters24
Statistical analysis
  • Atropine Group vs Placebo Group · Adjusted mean difference: -0.02 · 95% CI -0.19 to 0.15Atropine - Placebo Adjusted mean difference, adjusting for baseline refractive error, age, iris color (brown vs. not brown), and race (East Asian vs. non-East Asian).
SecondaryTreatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent

Treatment group comparison of change from baseline to 30 months in spherical equivalent in each eye as measured by a masked examiner using cycloplegic autorefraction (off-treatment comparison). Calculated based on the model estimates at 24 months.

Time frame:
At 30 months
Reported as:
Count of participants · Participants
Treatment Group Comparison of Change From Baseline to 30 Months in Spherical Equivalent
ParticipantsAtropine GroupPlacebo Group
<=-3.50 Diopters10
>-3.50 to -3.00 Diopters21
>-3.00 to -2.50 Diopters50
>-2.50 to -2.00 Diopters53
>-2.00 to -1.50 Diopters86
>-1.50 to -1.00 Diopters2211
>-1.00 to -0.50 Diopters3520
>-0.50 to 0.00 Diopters3613
>0 Diopters43
Statistical analysis
  • Atropine Group vs Placebo Group · Adjusted mean difference: -0.04 · 95% CI -0.25 to 0.17Atropine-Placebo Adjusted mean difference, adjusting for baseline refractive error, age, iris color (brown vs. not brown), and race (East Asian vs. non-East Asian).
PrimaryPrimary Outcome Measure Stratified by Sex

NIH-required analysis. Primary outcome measure (stratified by sex): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Time frame:
at 24 months
Reported as:
Mean · Diopters
Primary Outcome Measure Stratified by Sex
DioptersAtropine GroupPlacebo Group
Female-0.74 ± 0.57-0.74 ± 0.70
Male-0.84 ± 0.70-0.75 ± 0.44
PrimaryPrimary Outcome Measure Stratified by Race

NIH-required analysis. Primary outcome measure (stratified by race): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Time frame:
by 24 months
Reported as:
Mean · Diopter
Primary Outcome Measure Stratified by Race
DiopterAtropine GroupPlacebo Group
White-0.67 ± 0.55-0.74 ± 0.52
Black/African American-0.84 ± 0.63-1.07 ± 0.74
Asian-1.18 ± 0.80-0.26 ± 0.51
More than one race-0.84 ± 0.68-0.61 ± 0.58
Unknown/not reported-0.10—
PrimaryPrimary Outcome Measure Stratified by Ethnicity

NIH-required analysis. Primary outcome measure (stratified by ethnicity): The primary analysis will be a treatment group comparison of change from baseline to 24-months in spherical equivalent refractive error (SER), as measured by a masked examiner using cycloplegic autorefraction (on-treatment comparison). The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis. The treatment group difference (atropine - placebo) and a 95% confidence interval will be calculated based on the model estimates at 24 months.

Time frame:
at 24 months
Reported as:
Mean · Diopters
Primary Outcome Measure Stratified by Ethnicity
DioptersAtropine GroupPlacebo Group
Not Hispanic or Latino-0.81 ± 0.66-0.78 ± 0.62
Hispanic or Latino-0.63 ± 0.44-0.54 ± 0.42
PrimaryPrimary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months

The mean of the three readings from autorefraction in each eye will be calculated and then the mean of both eyes for each participant will be used for the analysis.

Time frame:
24 months
Reported as:
Mean · diopters
Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months
dioptersAtropine GroupPlacebo Group
Primary Outcome: Mean Change in Spherical Equivalent Refractive Error at 24 Months-3.64 ± 1.46-3.54 ± 1.08

Adverse events

Collected over Adverse event data was collected for the duration of the study, baseline to 30 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atropine Group0/125 (0%)2/125 (1.6%)109/125 (87.2%)
Placebo Group0/62 (0%)0/62 (0%)56/62 (90.3%)
Most frequent serious events
Most frequent serious events
EventAtropine GroupPlacebo Group
HospitalizationGeneral disorders2/1250/62
Most frequent other events
Showing 10 of 31
Most frequent other events
EventAtropine GroupPlacebo Group
Eye IrritiationEye disorders90/12551/62
PhotophobiaEye disorders32/12517/62
Vision BlurredEye disorders17/12510/62
Allergic ConjunctivitisEye disorders10/1255/62
Ocular DiscomfortEye disorders8/1255/62
Eye PainEye disorders9/1250/62
Meibomian gland dysfunctionEye disorders3/1253/62
Visual ImpairmentEye disorders6/1252/62
BlepharitisEye disorders6/1251/62
HordeolumEye disorders2/1252/62

Baseline characteristics

Age, Continuous
Age, Continuous(years)Atropine GroupPlacebo GroupTotal
Mean10.1 ± 1.810.1 ± 1.810.1 ± 1.8
Age, Customized
Age, Customized(Participants)Atropine GroupPlacebo GroupTotal
5 to <7 years639
7 to <9 years281341
9 to <11 years502070
11 to <13 years412667
Sex: Female, Male
Sex: Female, Male(Participants)Atropine GroupPlacebo GroupTotal
Female6536101
Male602686
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Atropine GroupPlacebo GroupTotal
White (not Hispanic or Latino)582886
White Hispanic or Latino21930
Black201434
East Asian16420
West Asian / South Asian426
More Than one race6511
Eye Color
Eye Color(Participants)Atropine GroupPlacebo GroupTotal
Brown8241123
Not Brown432164
Number of Biological Parents with Myopia
Number of Biological Parents with Myopia(Participants)Atropine GroupPlacebo GroupTotal
0161127
1512475
2522072
Myopia history unknown for one or both parents6713
Current Refractive Correction (Single-vision Spectacles or Contact Lenses)
Current Refractive Correction (Single-vision Spectacles or Contact Lenses)(Participants)Atropine GroupPlacebo GroupTotal
Yes12561186
No011
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes)
Distance Visual Acuity in Habitual Refractive Correction (Mean of Both Eyes)(Participants)Atropine GroupPlacebo GroupTotal
<-0.2 logMAR011
-0.2 to < -0.1 logMAR18523
-0.1 to < 0.0 logMAR623597
0.0 to < 0.1 logMAR361652
0.1 to < 0.2 logMAR9514

3 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • The Emory Eye Center Dept of Ophthalmology
    Atlanta, Georgia 30322, United States
  • St Luke's Hospital
    Boise, Idaho 83702, United States
  • Illinois College of Optometry
    Chicago, Illinois 60616, United States
  • Ticho Eye Associates
    Chicago Ridge, Illinois 60415, United States
  • Boston Children's Hospital Waltham
    Boston, Massachusetts 02453, United States
  • Pediatric Ophthalmology Associates, Inc.
    Columbus, Ohio 43205, United States
  • Eye Care Associates, Inc.
    Poland, Ohio 44514, United States
  • Dean A. McGee Eye Institute, University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Casey Eye Institute
    Portland, Oregon 97239, United States
  • Vanderbilt University Medical Center - Vanderbilt Eye Institute
    Nashville, Tennessee 37232, United States
  • University of Houston College of Optometry
    Houston, Texas 77204, United States
  • Rocky Mountain Eye Care Associates
    Salt Lake City, Utah 84107, United States
09

References and documents

Publications

  • Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, Kehler LAF, Jordan CO, Raghuram A, Summers AI, Lee KA, Petersen DB, Erzurum SA, Pang Y, Lenhart PD, Ticho BH, Beck RW, Kraker RT, Holmes JM, Cotter SA; Pediatric Eye Disease Investigator Group. Low-Dose 0.01% Atropine Eye Drops vs Placebo for Myopia Control: A Randomized Clinical Trial. JAMA Ophthalmol. 2023 Aug 1;141(8):756-765. doi: 10.1001/jamaophthalmol.2023.2855. PubMed 37440213 ↗
  • Weise KK, Repka MX, Zhu Y, Manny RE, Raghuram A, Chandler DL, Summers AI, Lee KA, Kehler LAF, Pang Y, Allen MS, Anderson HA, Erzurum SA, Golden RP, Koutnik CA, Kuo AF, Lenhart PD, Mokka PL, Petersen DB, Ticho BH, Wiecek EK, Yin H, Beaulieu WT, Kraker RT, Holmes JM, Cotter SA; Pediatric Eye Disease Investigator Group. Baseline factors associated with myopia progression and axial elongation over 30 months in children 5 to 12 years of age. Optom Vis Sci. 2024 Oct 1;101(10):619-626. doi: 10.1097/OPX.0000000000002187. PubMed 39480129 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the PEDIG public website after the completion of each protocol and publication of the primary manuscript.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After completion of the protocol and publication of the primary manuscript, the data will be made available for the duration of the grant and any future grants.

Access criteria: Users accessing the data must enter an email address.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Apr 2022, 46 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 25 phase 3 interventional studies under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 57. This study's 46 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2017
First posted
Nov 7, 2017
StartActual
Jun 1, 2018
Primary completionActual
Apr 15, 2022
CompletionActual
Sep 12, 2022
Results first posted
May 11, 2023
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03334253
Collaborators
Pediatric Eye Disease Investigator Group, National Eye Institute (NEI)
Responsible party
Sponsor
First posted
Nov 7, 2017
Start date
Jun 1, 2018
Primary completion
Apr 15, 2022
Completion
Sep 12, 2022
Results posted
May 11, 2023
Last update
Jul 31, 2026

Study contacts

Michael X Repka, MD, MBA
study chair · Wilmer Eye Institute
Katherine K Weise, OD, MBA
study chair · University of Alabama Birmingham Pediatric Eye Care, Birmingham Health Care

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atropine

Start the discussion